Trimodality Therapy in Bladder Cancer Who, What, and When?

被引:29
|
作者
Premo, Christopher [1 ]
Apolo, Andrea B. [2 ]
Agarwal, Piyush K. [3 ]
Citrin, Deborah E. [1 ]
机构
[1] NIH, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Bladder Canc Sect, Genitourinary Malignancies Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[3] NCI, Bladder Canc Sect, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
TRANSITIONAL-CELL-CARCINOMA; COMBINED-MODALITY THERAPY; LONG-TERM OUTCOMES; SELECTIVE ORGAN PRESERVATION; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; RADIATION-THERAPY; TRANSURETHRAL RESECTION; RADICAL RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.ucl.2015.02.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Radical cystectomy is a standard treatment of nonmetastatic, muscle-invasive bladder cancer. Treatment with trimodality therapy consisting of maximal transurethral resection of the bladder tumor followed by concurrent chemotherapy and radiation has emerged as a method to preserve the native bladder in highly motivated patients. Several factors can affect the likelihood of long-term bladder preservation after trimodality therapy and therefore should be taken into account when selecting patients. New radiation techniques such as intensity modulated radiation therapy and image-guided radiation therapy may decrease the toxicity of radiotherapy in this setting. Novel chemotherapy regimens may improve response rates and minimize toxicity.
引用
收藏
页码:169 / +
页数:13
相关论文
共 50 条
  • [41] Trimodality therapy for advanced gallbladder cancer
    Sasson, AR
    Hoffman, JP
    Ross, E
    Meropol, NJ
    Szarka, CE
    Freedman, G
    Pinover, W
    Pingpank, JF
    Eisenberg, BL
    AMERICAN SURGEON, 2001, 67 (03) : 277 - 283
  • [42] Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: a decision analysis
    Lester-Coll, Nataniel H.
    Yu, James B.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2855 - S2857
  • [43] Trimodality therapy for esophageal cancer - Reply
    Jones, DR
    ANNALS OF THORACIC SURGERY, 1998, 65 (03): : 900 - 900
  • [44] Cost-effectiveness of radical cystectomy versus trimodality therapy for muscle invasive bladder cancer
    Suskovic, Nathan
    Raldow, Ann C.
    Royce, Trevor Joseph
    Smith, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Trimodality treatment and selective organ preservation for bladder cancer
    Roedel, Claus
    Weiss, Christian
    Sauer, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) : 5536 - 5544
  • [46] Mutational Landscape and Genetic Determinants of Response to Trimodality Therapy in Muscle-Invasive Bladder Cancer
    Miyamoto, D. T.
    Kamran, S. C.
    Mouw, K. W.
    Wu, C. L.
    Wu, S.
    Ukleja, J.
    Kusaka, E.
    Otani, K.
    Borger, D.
    Lennerz, J. K.
    Van Allen, E. M.
    Willers, H.
    Hong, T. S.
    Shipley, W. U.
    Efstathiou, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E861 - E861
  • [47] Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.
    Efstathiou, Jason A.
    Gibb, Ewan
    Miyamoto, David Tomoaki
    Wu, Chin-Lee
    Drumm, Michael
    Lehrer, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [48] Who, what, when?
    Chevin, Denise
    Building Engineer, 2024, 99 (04): : 28 - 30
  • [49] Second Breast Conserving Therapy: Who, What, When, and How?
    Lyons, Janice A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (05): : 1211 - 1212
  • [50] Who, what, when?
    Marshall, Rick
    PHYSICS WORLD, 2015, 28 (10) : 20 - 20